Tbio DMBT1 Deleted in malignant brain tumors 1 protein

Protein Summary

Description

May be considered as a candidate tumor suppressor gene for brain, lung, esophageal, gastric, and colorectal cancers. May play roles in mucosal defense system, cellular immune defense and epithelial differentiation. May play a role as an opsonin receptor for SFTPD and SPAR in macrophage tissues throughout the body, including epithelial cells lining the gastrointestinal tract. May play a role in liver regeneration. May be an important factor in fate decision and differentiation of transit-amplifying ductular (oval) cells within the hepatic lineage. Required for terminal differentiation of columnar epithelial cells during early embryogenesis. May function as a binding protein in saliva for the regulation of taste sensation. Binds to HIV-1 envelope protein and has been shown to both inhibit and facilitate viral transmission. Displays a broad calcium-dependent binding spectrum against both Gram-positive and Gram-negative bacteria, suggesting a role in defense against bacterial pathogens. Binds to a range of poly-sulfated and poly-phosphorylated ligands which may explain its broad bacterial-binding specificity. Inhibits cytoinvasion of S.enterica. Associates with the actin cytoskeleton and is involved in its remodeling during regulated exocytosis. Interacts with pancreatic zymogens in a pH-dependent manner and may act as a Golgi cargo receptor in the regulated secretory pathway of the pancreatic acinar cell. Loss of sequences from human chromosome 10q has been associated with the progression of human cancers. This gene was originally isolated based on its deletion in a medulloblastoma cell line. This gene is expressed with transcripts of 6.0, 7.5, and 8.0 kb in fetal lung and with one transcript of 8.0 kb in adult lung, although the 7.5 kb transcript has not been characterized. The encoded protein precursor is a glycoprotein containing multiple scavenger receptor cysteine-rich (SRCR) domains separated by SRCR-interspersed domains (SID). Transcript variant 2 (8.0 kb) has been shown to bind surfactant protein D independently of carbohydrate recognition. This indicates that DMBT1 may not be a classical tumor suppressor gene, but rather play a role in the interaction of tumor cells and the immune system. [provided by RefSeq, Mar 2016]

Uniprot Accession IDs

• Q9UGM3
• A6NDG4
• A6NDJ5
• A8E4R5
• B1ARE7
• B1ARE8
• B1ARE9
• B1ARF0
• B7Z8Y2
• F8WEF7
• Q59EX0
• Q5JR26
• Q6MZN4
• Q96DU4
• Q9UGM2
• Q9UJ57
• Q9UKJ4
• Q9Y211
• Q9Y4V9

Gene Name

• DMBT1

Ensembl ID

• ENST00000330163
• ENSP00000327747
• ENSG00000187908
• ENST00000338354
• ENSP00000342210
• ENST00000344338
• ENSP00000343175
• ENST00000368909
• ENSP00000357905
• ENST00000368955
• ENSP00000357951
• ENST00000368956
• ENSP00000357952
• ENST00000619379
• ENSP00000484603

Symbol

• GP340
• SAG
• GP340
• SALSA
• muclin

Knowledge Table

Most Knowledge About	Knowledge Value (0 to 1 scale)
disease perturbation	0.83
cell type or tissue	0.77
protein domain	0.73
cellular component	0.7
tissue sample	0.65

Protein Classes

PANTHER Classes

Protein / Receptor / Deleted In Malignant Brain Tumors 1 Protein

Protein / Oxidoreductase / Oxidase / Deleted In Malignant Brain Tumors 1 Protein

Protein / Hydrolase / Protease / Serine Protease / Deleted In Malignant Brain Tumors 1 Protein

DTO Classes

Protein / Enzyme / Oxidoreductase / Oxidase / Deleted In Malignant Brain Tumors 1 Protein

IDG Development Level Summary

Tdark

These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 271.22   (req: < 5)

Gene RIFs: 105   (req: <= 3)

Antibodies: 176   (req: <= 50)

Tbio

These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 271.22   (req: >= 5)

Gene RIFs: 105   (req: > 3)

Antibodies: 176   (req: > 50)

- OR - satisfy the following criterion:

Gene Ontology Terms: 21

Tchem

Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions

Active Ligand: 0

Tclin

Target has at least one approved drug - AND - satisfies the preceding conditions

Active Drug: 0